Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Baskent University, Turkey
New osteoporosis therapy study findings have been reported by scientists at Baskent University, Department of Endocrinology and Metabolism
November 7th, 2006
New investigation results, "Effects of raloxifene on platelet functions in patients with postmenopausal osteoporosis," are detailed in a study published in Platelets. According to recent research from Ankara, Turkey, "Many studies have addressed the effects of estrogenic compounds on platelet function. Raloxifene is a selective estrogen receptor modulator (SERM), which is currently used for the treatment of postmenopausal osteoporosis." "At present, there are no clinical data about the effects of raloxifene on platelet function. The purpose of this study was to determine if raloxifene at therapeutic doses affects platelet function in patients with postmenopausal...
Source: Drug Law Weekly (2006-11-07)
|
